Roche
NEWS
At the six-year mark, 90.6% of patients in the Perjeta cohort have not had breast cancer return, compared to 87.8% in the placebo arm. This comes to an absolute benefit of 2.8%.
Filing submission includes 12-month data from pivotal FIREFISH and SUNFISH trials in a broad population of people living with Types 1, 2 or 3 SMA
Tecentriq is the company’s PD-L1 checkpoint inhibitor. Avastin is an antibody that binds to VEGF and interferes with tumor blood supply.
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
It was a busy week for clinical trial announcements. Here’s a look.
Under the terms of the agreement, Roche will make an upfront cash payment of $390 million, plus additional contingent payments of up to $1 billion based on the achievement of certain predetermined development, regulatory and commercial milestones.
Roche intends to hold two global meetings with members of the DMD community to provide the stakeholders with as much information as possible.
Under the terms of the deal, Roche will pay Dicerna $200 million upfront and up to another $1.47 billion for various development, regulatory and commercial milestones.
This marks the eighth such extension for the deal.
JOBS
IN THE PRESS